Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of reducing eosinophil levels

a technology of eosinophils and eosinophils, which is applied in the field of reducing eosinophil levels in human subjects, can solve the problems of steroid administration often associated with side effects, no anti-inflammatory agent, so far, and eosinophils are not known to induce apoptosis of activated eosinophils, etc., and achieve the effect of reducing the number of eosinophils

Inactive Publication Date: 2010-11-18
BIOWA +1
View PDF4 Cites 76 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0010]The invention provides a method of reducing the numbers of eosinophils in a human subject comprising administration to said patient an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region.

Problems solved by technology

However, in most cases these agents do not act on cytokine-independent eosinophils that have been activated and infiltrated into inflamed areas.
However, no anti-inflammatory agent, so far, has been known to induce apoptosis of activated eosinophils.
However, steroid administration is often associated with side effects.
Specifically, the treatment has some other problems, such that patient's pathological condition may return to the original state when steroid administration is discontinued, and prolonged steroid administration may induce steroid resistance.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of reducing eosinophil levels
  • Methods of reducing eosinophil levels
  • Methods of reducing eosinophil levels

Examples

Experimental program
Comparison scheme
Effect test

specific embodiments

[0158]1. A method of reducing the numbers of eosinophils in a human subject comprising administration to said subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region.

[0159]2. The method of embodiment 1, wherein said IL-5R binding molecule is an antibody.

[0160]3. The method of embodiment 2, wherein said antibody is a monoclonal antibody.

[0161]4. The method of embodiment 3, wherein said antibody is a chimeric antibody.

[0162]5. The method of embodiment 3, wherein said antibody is a humanized antibody.

[0163]6. The method of embodiment 3, wherein said antibody is a human antibody.

[0164]7. The method of embodiment 1, wherein said region that specifically binds to the IL-5R comprises the amino acid sequence of IL-5, or fragments, substitutions, or derivatives thereof.

[0165]8. The method of embodiment 7, wherein said region that specifically binds to the IL-5R comprises a nonfunctional variant of IL-5.

[0166]9. Th...

example 1

MEDI-563, an Anti-Interleukin-5-Receptor Antibody, is Well Tolerated and Induces Reversible Blood Eosinopenia in Mild Asthmatics in a Phase I Trial

[0261]Background: Eosinophils are believed to play a key role in the pathogenesis of asthma. Interleukin-5 (IL-5) is a major cytokine in eosinophil biology, and expression of its receptor (IL-5R) is largely restricted to eosinophils, basophils, and mast cells. The suboptimal efficacy of IL-5-targeted therapies in asthma has been attributed to an incomplete depletion of eosinophils in lung tissue. Complete lung eosinophil depletion should provide additional insight into the role of these cells in asthma and could represent a novel therapeutic strategy.

Objectives: To assess the safety and biological activity of MEDI-563 (previously known as BIW-8405), a humanized afucosylated IgG1 anti-IL-5R alpha chain monoclonal antibody. MEDI-563 was developed by BioWa, Inc. through proprietary Potelligent® technology that significantly enhances antibody...

example 2

Antibody Dependent Cell-Mediated Cytotoxicity

[0262]KC1333 effector cells (human NK cell overexpressing human FcgRIIIa and FceRIg) were co-incubated for 4 hours with target CTLL-2 cell line (mouse lymphoma genetically modified to overexpress human IL-5Ra) at a ratio of 5 effectors:1 target, in the presence of MEDI-563 or control antibody. Antibody mediated cytotoxicity was assessed using a Calcein AM cell viability assay. Results are summarized in FIG. 9A. Using a similar methodology, a further control (fucosylated MEDI-563) was analyzed. Results are summarized in FIG. 9B.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
flow rateaaaaaaaaaa
mass median aerodynamic diameteraaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e g, esophagus, stomach, small intestine and colon), or lung.

Description

FIELD OF THE INVENTION[0001]The present invention relates to methods of reducing eosinophil levels in human subjects.BACKGROUND OF THE INVENTION[0002]Eosinophils are implicated in various diseases including allergic diseases, and are thought to play an important role in generating morbidity of allergic diseases, such as chronic bronchial asthma and atopic dermatitis [Adv. Immunol., 39, 177 (1986), Immunol. Today, 13, 501 (1992)]. In addition to the above diseases, eosinophils are also implicated in diseases generally referred to as hypereosinophilic syndrome (HES), such as eosinophilia, eosinophilic enterogastritis, eosinophilic leukemia, eosinophilic granuloma and Kimura's disease [Ann. Intern. Med., 97, 78 (1982)].[0003]Eosinophilic granuloma is nonneoplastic cryptogenic lesion, which is an osteolytic and focal, and is known to be associated with remarkable tissue eosinophilia [U.S. Armed Forces Med. J., 2, 1085 (1951)]. According to the registry of bone tumor patients in Japan (1...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395C07K16/18A61P37/06
CPCA61K2039/505C07K16/2866C07K2316/96C07K16/28C07K2317/732C07K7/08C07K2317/24A61P11/00A61P11/06A61P29/00A61P37/00A61P37/02A61P37/06A61P37/08A61P43/00A61P7/00A61K39/395C07K16/18C12N5/0642
Inventor KOIKE, MASAMICHISPITALNY, GEORGE L.WHEELER, ALISTAIRWHITE, BARBARA
Owner BIOWA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com